Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

NCT01517555 · Completed

Last updated 2026-05-28

This clinical trial tested how the diabetes medication liraglutide affects the absorption of paracetamol in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 18 people

Who can join Ages 18–70 · all sexes

Timeline Started 2006-10 · est. completion 2007-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01517555 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial glucose.

Treatments tested

liraglutide Drug

Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
placebo Drug

Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
paracetamol Drug

One single dose of 1 g. Tablet

Main thing measured	Area under the curve of paracetamol
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01517555 ↗